Jack Meehan
Stock Analyst at Barclays
(3.05)
# 1,210
Out of 5,241 analysts
128
Total ratings
69.23%
Success rate
22.03%
Average return
Main Sectors:
Stocks Rated by Jack Meehan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LH Labcorp Holdings | Maintains: Equal-Weight | $275 → $290 | $250.40 | +15.81% | 17 | Oct 2, 2025 | |
| A Agilent Technologies | Maintains: Underweight | $120 → $125 | $111.70 | +11.91% | 20 | Feb 28, 2024 | |
| WAT Waters | Maintains: Equal-Weight | $275 → $288 | $329.22 | -12.52% | 10 | Aug 3, 2023 | |
| AVTR Avantor | Initiates: Overweight | $33 | $7.62 | +333.07% | 3 | Mar 3, 2021 | |
| ILMN Illumina | Initiates: Underweight | $325 | $142.54 | +128.01% | 8 | Mar 3, 2021 | |
| INMD InMode | Maintains: Overweight | $18 → $19 | $13.90 | +36.69% | 3 | Aug 17, 2020 | |
| DGX Quest Diagnostics | Maintains: Equal-Weight | $93 → $99 | $186.61 | -46.95% | 7 | Apr 23, 2020 | |
| ICLR ICON Public Limited Company | Maintains: Overweight | $170 → $180 | $116.38 | +54.67% | 2 | Apr 23, 2020 | |
| MYGN Myriad Genetics | Maintains: Underweight | $14 → $10 | $3.58 | +179.33% | 8 | Mar 26, 2020 | |
| IQV IQVIA Holdings | Maintains: Overweight | $192 → $166 | $169.12 | -1.84% | 4 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $170 → $154 | $150.85 | +2.09% | 7 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $430 | $247.53 | +73.72% | 6 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $430 | $260.90 | +64.81% | 6 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | n/a | $10.32 | - | 10 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $52 → $48 | $42.88 | +11.94% | 4 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $720 → $680 | $1,031.64 | -34.09% | 4 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $28 → $30 | $56.28 | -46.70% | 3 | Oct 2, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $295 → $300 | $438.34 | -31.56% | 5 | Mar 18, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $40 | $0.82 | +4,778.05% | 1 | Dec 11, 2017 |
Labcorp Holdings
Oct 2, 2025
Maintains: Equal-Weight
Price Target: $275 → $290
Current: $250.40
Upside: +15.81%
Agilent Technologies
Feb 28, 2024
Maintains: Underweight
Price Target: $120 → $125
Current: $111.70
Upside: +11.91%
Waters
Aug 3, 2023
Maintains: Equal-Weight
Price Target: $275 → $288
Current: $329.22
Upside: -12.52%
Avantor
Mar 3, 2021
Initiates: Overweight
Price Target: $33
Current: $7.62
Upside: +333.07%
Illumina
Mar 3, 2021
Initiates: Underweight
Price Target: $325
Current: $142.54
Upside: +128.01%
InMode
Aug 17, 2020
Maintains: Overweight
Price Target: $18 → $19
Current: $13.90
Upside: +36.69%
Quest Diagnostics
Apr 23, 2020
Maintains: Equal-Weight
Price Target: $93 → $99
Current: $186.61
Upside: -46.95%
ICON Public Limited Company
Apr 23, 2020
Maintains: Overweight
Price Target: $170 → $180
Current: $116.38
Upside: +54.67%
Myriad Genetics
Mar 26, 2020
Maintains: Underweight
Price Target: $14 → $10
Current: $3.58
Upside: +179.33%
IQVIA Holdings
Mar 26, 2020
Maintains: Overweight
Price Target: $192 → $166
Current: $169.12
Upside: -1.84%
Mar 26, 2020
Maintains: Equal-Weight
Price Target: $170 → $154
Current: $150.85
Upside: +2.09%
Mar 26, 2020
Maintains: Overweight
Price Target: $435 → $430
Current: $247.53
Upside: +73.72%
Mar 26, 2020
Maintains: Overweight
Price Target: $435 → $430
Current: $260.90
Upside: +64.81%
Mar 26, 2020
Downgrades: Equal-Weight
Price Target: n/a
Current: $10.32
Upside: -
Mar 26, 2020
Upgrades: Overweight
Price Target: $52 → $48
Current: $42.88
Upside: +11.94%
Mar 26, 2020
Upgrades: Equal-Weight
Price Target: $720 → $680
Current: $1,031.64
Upside: -34.09%
Oct 2, 2019
Maintains: Underweight
Price Target: $28 → $30
Current: $56.28
Upside: -46.70%
Mar 18, 2019
Maintains: Overweight
Price Target: $295 → $300
Current: $438.34
Upside: -31.56%
Dec 11, 2017
Initiates: Equal-Weight
Price Target: $40
Current: $0.82
Upside: +4,778.05%